{"id":43154,"date":"2025-10-13T16:39:36","date_gmt":"2025-10-13T08:39:36","guid":{"rendered":"https:\/\/flcube.com\/?p=43154"},"modified":"2025-10-13T16:39:37","modified_gmt":"2025-10-13T08:39:37","slug":"chinas-nmpa-approves-mufemilast-hemay005-hemeis-first-domestic-pde4-inhibitor","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=43154","title":{"rendered":"China\u2019s NMPA Approves Mufemilast (Hemay005) \u2014 Hemei\u2019s First Domestic PDE4 Inhibitor"},"content":{"rendered":"\n<p>The <strong>National Medical Products Administration (NMPA)<\/strong> announced that <strong>Jiangxi Hemei Pharmaceutical Co., Ltd.<\/strong> has received marketing approval for its Class\u202f1 innovative drug, <strong>Mufemilast (Hemay005) Tablets<\/strong>. The approval, effective immediately, authorises use in adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-product-profile\">Product Profile<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Active Ingredient<\/strong> \u2013 Mufemilast is a small\u2011molecule <strong>phosphodiesterase\u202f4 (PDE4) inhibitor<\/strong>.<\/li>\n\n\n\n<li><strong>First Domestic PDE4 Inhibitor<\/strong> \u2013 While Amgen\u2019s Apremilast and Pfizer\u2019s Crisaborole ointment have previously entered the Chinese market, Mufemilast is the first <strong>domestically\u2011developed<\/strong> PDE4 inhibitor approved by the NMPA.<\/li>\n\n\n\n<li><strong>Formulation<\/strong> \u2013 Oral tablets, facilitating easier administration than topical or injectable alternatives.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-clinical-indication\">Clinical Indication<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Approved Indication<\/strong> \u2013 Adult patients with <strong>moderate to severe plaque psoriasis<\/strong> who are candidates for <strong>phototherapy or systemic therapy<\/strong>.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-broader-development-pipeline\">Broader Development Pipeline<\/h3>\n\n\n\n<p>Mufemilast is being evaluated in multiple other inflammatory and autoimmune conditions:<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Indication<\/th><th>Trial Phase<\/th><\/tr><\/thead><tbody><tr><td>Beh\u00e7et\u2019s disease<\/td><td>Phase\u202fIII<\/td><\/tr><tr><td>Atopic dermatitis<\/td><td>Phase\u202fII<\/td><\/tr><tr><td>Ankylosing spondylitis<\/td><td>Phase\u202fII<\/td><\/tr><tr><td>Ulcerative colitis<\/td><td>Phase\u202fII<\/td><\/tr><tr><td>Chronic Obstructive Pulmonary Disease (COPD)<\/td><td>Phase\u202fI<\/td><\/tr><tr><td>Crohn\u2019s disease<\/td><td>Clinical\u2011trial approval<\/td><\/tr><tr><td>Psoriatic arthritis<\/td><td>Clinical\u2011trial approval<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-market-impact\">Market Impact<\/h3>\n\n\n\n<p>The approval positions Hemei as a key player in China\u2019s expanding biologics and small\u2011molecule arena, offering a new oral alternative for psoriasis treatment. The company\u2019s ongoing trials could broaden the drug\u2019s therapeutic portfolio, potentially capturing significant market share in multiple inflammatory disorders.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The National Medical Products Administration (NMPA) announced that Jiangxi Hemei Pharmaceutical Co., Ltd. has received&#8230;<\/p>\n","protected":false},"author":1,"featured_media":43156,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[11],"tags":[65,4381,15],"class_list":["post-43154","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-drug","tag-auto-immune","tag-hemei-pharmaceutical","tag-product-approvals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>China\u2019s NMPA Approves Mufemilast (Hemay005) \u2014 Hemei\u2019s First Domestic PDE4 Inhibitor - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"The National Medical Products Administration (NMPA) announced that Jiangxi Hemei Pharmaceutical Co., Ltd. has received marketing approval for its Class\u202f1 innovative drug, Mufemilast (Hemay005) Tablets. The approval, effective immediately, authorises use in adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=43154\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"China\u2019s NMPA Approves Mufemilast (Hemay005) \u2014 Hemei\u2019s First Domestic PDE4 Inhibitor\" \/>\n<meta property=\"og:description\" content=\"The National Medical Products Administration (NMPA) announced that Jiangxi Hemei Pharmaceutical Co., Ltd. has received marketing approval for its Class\u202f1 innovative drug, Mufemilast (Hemay005) Tablets. The approval, effective immediately, authorises use in adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=43154\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-13T08:39:36+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-13T08:39:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1302.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43154#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43154\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"China\u2019s NMPA Approves Mufemilast (Hemay005) \u2014 Hemei\u2019s First Domestic PDE4 Inhibitor\",\"datePublished\":\"2025-10-13T08:39:36+00:00\",\"dateModified\":\"2025-10-13T08:39:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43154\"},\"wordCount\":239,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43154#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1302.webp\",\"keywords\":[\"Auto-immune\",\"Hemei Pharmaceutical\",\"Product approvals\"],\"articleSection\":[\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=43154#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43154\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=43154\",\"name\":\"China\u2019s NMPA Approves Mufemilast (Hemay005) \u2014 Hemei\u2019s First Domestic PDE4 Inhibitor - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43154#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43154#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1302.webp\",\"datePublished\":\"2025-10-13T08:39:36+00:00\",\"dateModified\":\"2025-10-13T08:39:37+00:00\",\"description\":\"The National Medical Products Administration (NMPA) announced that Jiangxi Hemei Pharmaceutical Co., Ltd. has received marketing approval for its Class\u202f1 innovative drug, Mufemilast (Hemay005) Tablets. The approval, effective immediately, authorises use in adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43154#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=43154\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43154#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1302.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1302.webp\",\"width\":1080,\"height\":608,\"caption\":\"China\u2019s NMPA Approves Mufemilast (Hemay005) \u2014 Hemei\u2019s First Domestic PDE4 Inhibitor\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43154#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"China\u2019s NMPA Approves Mufemilast (Hemay005) \u2014 Hemei\u2019s First Domestic PDE4 Inhibitor\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"China\u2019s NMPA Approves Mufemilast (Hemay005) \u2014 Hemei\u2019s First Domestic PDE4 Inhibitor - Insight, China&#039;s Pharmaceutical Industry","description":"The National Medical Products Administration (NMPA) announced that Jiangxi Hemei Pharmaceutical Co., Ltd. has received marketing approval for its Class\u202f1 innovative drug, Mufemilast (Hemay005) Tablets. The approval, effective immediately, authorises use in adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=43154","og_locale":"en_US","og_type":"article","og_title":"China\u2019s NMPA Approves Mufemilast (Hemay005) \u2014 Hemei\u2019s First Domestic PDE4 Inhibitor","og_description":"The National Medical Products Administration (NMPA) announced that Jiangxi Hemei Pharmaceutical Co., Ltd. has received marketing approval for its Class\u202f1 innovative drug, Mufemilast (Hemay005) Tablets. The approval, effective immediately, authorises use in adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.","og_url":"https:\/\/flcube.com\/?p=43154","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-10-13T08:39:36+00:00","article_modified_time":"2025-10-13T08:39:37+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1302.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=43154#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=43154"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"China\u2019s NMPA Approves Mufemilast (Hemay005) \u2014 Hemei\u2019s First Domestic PDE4 Inhibitor","datePublished":"2025-10-13T08:39:36+00:00","dateModified":"2025-10-13T08:39:37+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=43154"},"wordCount":239,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=43154#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1302.webp","keywords":["Auto-immune","Hemei Pharmaceutical","Product approvals"],"articleSection":["Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=43154#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=43154","url":"https:\/\/flcube.com\/?p=43154","name":"China\u2019s NMPA Approves Mufemilast (Hemay005) \u2014 Hemei\u2019s First Domestic PDE4 Inhibitor - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=43154#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=43154#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1302.webp","datePublished":"2025-10-13T08:39:36+00:00","dateModified":"2025-10-13T08:39:37+00:00","description":"The National Medical Products Administration (NMPA) announced that Jiangxi Hemei Pharmaceutical Co., Ltd. has received marketing approval for its Class\u202f1 innovative drug, Mufemilast (Hemay005) Tablets. The approval, effective immediately, authorises use in adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=43154#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=43154"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=43154#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1302.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1302.webp","width":1080,"height":608,"caption":"China\u2019s NMPA Approves Mufemilast (Hemay005) \u2014 Hemei\u2019s First Domestic PDE4 Inhibitor"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=43154#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"China\u2019s NMPA Approves Mufemilast (Hemay005) \u2014 Hemei\u2019s First Domestic PDE4 Inhibitor"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1302.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/43154","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=43154"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/43154\/revisions"}],"predecessor-version":[{"id":43157,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/43154\/revisions\/43157"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/43156"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=43154"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=43154"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=43154"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}